Recurrent, platinum-sensitive, KRAS wild-type recurrent ovarian cancer.Chemotherapy (carboplatin and PLD or gemcitabine) alone in combination with Panitumumab.Randomised, open-label. This evidence concerns the gene KRAS and ovarian cancer.